Adaptive Biotechnologies Co. (NASDAQ:ADPT) has been assigned a consensus score of “Purchase” from the eight brokerages which might be overlaying the agency, MarketBeat Rankings studies. Three equities analysis analysts have rated the stock with a maintain suggestion and 5 have assigned a purchase suggestion to the corporate. The typical 1-year price goal amongst brokers which have up to date their protection on the stock within the final 12 months is $55.80.
ADPT has been the topic of various analyst studies. JPMorgan Chase & Co. restated an “chubby” score and set a $60.00 price goal (up beforehand from $50.00) on shares of Adaptive Biotechnologies in a analysis report on Wednesday, November 11th. BTIG Analysis elevated their price goal on shares of Adaptive Biotechnologies from $60.00 to $63.00 and gave the corporate a “purchase” score in a report on Thursday, November 12th. Morgan Stanley elevated their price goal on shares of Adaptive Biotechnologies from $42.00 to $46.00 and gave the corporate an “equal weight” score in a report on Wednesday, November 11th. Lastly, William Blair reiterated an “outperform” score on shares of Adaptive Biotechnologies in a report on Tuesday, August 11th.
In associated information, CEO Chad M. Robins bought 1,900 shares of the stock in a transaction dated Tuesday, September 29th. The shares have been bought at a mean price of $50.18, for a complete value of $95,342.00. Following the sale, the chief govt officer now immediately owns 1,780,080 shares of the corporate’s stock, valued at roughly $89,324,414.40. The sale was disclosed in a submitting with the SEC, which is on the market by means of this hyperlink. Additionally, insider Francis Lo bought 25,000 shares of the stock in a transaction dated Monday, October 12th. The shares have been bought at a mean price of $52.80, for a complete transaction of $1,320,000.00. Following the completion of the sale, the insider now immediately owns 25,000 shares within the firm, valued at $1,320,000. The disclosure for this sale will be discovered right here. Over the past three months, insiders bought 3,126,203 shares of firm stock worth $153,872,302. 34.70% of the stock is owned by company insiders.
A number of institutional buyers have not too long ago added to or lowered their stakes in ADPT. Neuberger Berman Group LLC boosted its stake in shares of Adaptive Biotechnologies by 246.2% throughout the 2nd quarter. Neuberger Berman Group LLC now owns 1,723,347 shares of the corporate’s stock worth $83,389,000 after buying an extra 1,225,502 shares over the past quarter. Vanguard Group Inc. boosted its stake in shares of Adaptive Biotechnologies by 26.2% throughout the 2nd quarter. Vanguard Group Inc. now owns 5,641,434 shares of the corporate’s stock worth $272,933,000 after buying an extra 1,169,653 shares over the past quarter. Massachusetts Monetary Companies Co. MA boosted its stake in shares of Adaptive Biotechnologies by 31.9% throughout the third quarter. Massachusetts Monetary Companies Co. MA now owns 2,952,304 shares of the corporate’s stock worth $143,571,000 after buying an extra 713,320 shares over the past quarter. Summit Companions Public Asset Administration LLC boosted its stake in shares of Adaptive Biotechnologies by 235.9% throughout the third quarter. Summit Companions Public Asset Administration LLC now owns 839,504 shares of the corporate’s stock worth $40,825,000 after buying an extra 589,563 shares over the past quarter. Lastly, ARK Funding Administration LLC boosted its stake in shares of Adaptive Biotechnologies by 186.2% throughout the third quarter. ARK Funding Administration LLC now owns 884,722 shares of the corporate’s stock worth $43,024,000 after buying an extra 575,584 shares over the past quarter. 73.67% of the stock is presently owned by institutional buyers.
Shares of Adaptive Biotechnologies stock opened at $46.40 on Friday. The corporate has a market cap of $6.35 billion, a P/E ratio of -48.84 and a beta of 0.27. Adaptive Biotechnologies has a one 12 months low of $15.19 and a one 12 months excessive of $54.20. The agency has a fifty day shifting common of $49.50 and a two-hundred day shifting common of $43.40.
Adaptive Biotechnologies (NASDAQ:ADPT) final introduced its quarterly earnings information on Sunday, November 15th. The corporate reported ($0.27) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.01. The corporate had income of $26.30 million throughout the quarter, in comparison with the consensus estimate of $23.58 million. Adaptive Biotechnologies had a adverse web margin of 132.32% and a adverse return on fairness of 20.15%. Adaptive Biotechnologies’s quarterly income was up .9% on a year-over-year foundation. Throughout the identical quarter within the prior 12 months, the agency earned ($0.11) EPS. As a gaggle, equities analysts anticipate that Adaptive Biotechnologies will put up -1.08 EPS for the present 12 months.
Adaptive Biotechnologies Firm Profile
Adaptive Biotechnologies Company, a commercial-stage firm, develops an immune drugs platform for the prognosis and remedy of assorted illnesses. The corporate affords immunoSEQ analysis service and equipment that’s used to reply analysis questions, in addition to to find new prognostic and diagnostic alerts.
Additional Studying: What’s a CD ladder?
This instantaneous information alert was generated by narrative science know-how and monetary information from MarketBeat to be able to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to [email protected]